

## Glaucoma Prescribing Guideline

### Disclaimer

This guideline is registered at North Central London (NCL) Joint Formulary Committee (JFC) and is intended solely for use by healthcare professionals to aid the treatment of patients within NCL. However, clinical guidelines are for guidance only, their interpretation and application remain the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Clinicians are advised to refer to the manufacturer's current prescribing information before treating individual patients.

The authors and NCL JFC accept no liability for use of this information from this beyond its intended use. While we have tried to compile accurate information in this guideline, and to keep it updated in a timely manner, we cannot guarantee that it is fully complete and correct at all times. If you identify information within this guideline that is inaccurate, please report this to the [admin.ncl-mon@nhs.net](mailto:admin.ncl-mon@nhs.net). If a patient is harmed as a consequence of following this guideline, please complete a local incident report and inform [admin.ncl-mon@nhs.net](mailto:admin.ncl-mon@nhs.net).

This guideline should not be used or reproduced for commercial or marketing purposes.

NCL JFC is funded by and provides advice to Acute Trusts and Clinical Commissioning Groups in NCL.

## Document control

Date	Version	Amendments
Oct 2013	1.0	New guideline
Oct 2014	1.1	Update
Oct 2015	1.2	Update
Jun 2017	1.3	Minor amendment (advice regarding treatment period of apraclonidine 0.5%)
Jan 2018	2.0	Update – carteolol 1% and 2% removed
Oct 2020	3.0	Update – addition of Fixapost®, addition of a statement on the use of apraclonidine 1%, and format changes

## Document management

Groups / Individuals who have overseen the development of this guidance:	MEH Formulary and Clinical Services teams
Groups which were consulted and have given approval:	NCL JFC
File name:	11_Glaucoma_prescribing_guideline
Version number:	3.0
Available on:	<a href="https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/11_Glaucoma_prescribing_guideline.pdf">https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/11_Glaucoma_prescribing_guideline.pdf</a>
Disseminated to:	NCL JFC Formulary Pharmacists and CCG Leads
Equality impact assessment:	Low
NCL Joint Formulary Committee approval date:	October 2020
Review date:	October 2023

## Part 1 – Pharmacological Pathway for the Treatment and Management of Open Angle Glaucoma and Ocular Hypertension

### Summary of Glaucoma Prescribing Guideline:

- Before offering medication any relevant comorbidities or potential drug interactions need to be checked carefully.
- A single drug should be started and its effectiveness at lowering intraocular pressure (IOP) and any side effects should be assessed usually upon follow-up. If there is no IOP response and the patient's adherence and eye drop instillation technique have been checked and deemed appropriate, the drug should be stopped and another tried from a different class. If there is a satisfactory IOP drop but insufficient to meet the target pressure then a second drug may be added.
- Medical therapy of more than three topical agents- one separate and one combination should trigger consideration for either laser or surgery. Maximal medical treatment would consist of all 4 classes of topical pressure lowering medications and possible oral acetazolamide.
- The guideline should be adhered to for all new patients. No change in treatment plan is recommended for patients already on different medications when there is satisfactory IOP response. Non-responders should be switched to a different class of drug.
- All patients must be prescribed generic drugs unless otherwise required for clinical reasons which must be identified on a case by case basis and appropriately communicated to GPs.

### Step 1

1st line: Prostaglandin analogues Safer than  $\beta$ -blockers and more effective at lowering IOP.

2nd line:  $\beta$ -blockers However, can be used as first line for unilateral glaucoma patients or as a result of adverse effects to prostaglandin analogues. Not to be prescribed if there is history of bronchospasm and should be stopped immediately if the patient develops any cardiac or respiratory related side effects.



### Step 2

USE prostaglandin analogue  
PLUS  $\beta$ -blocker



### Step 3

When prostaglandin analogue and  $\beta$ -blocker are insufficient to achieve desired target IOP

ADD carbonic anhydrase inhibitor  
AND/OR  $\alpha$ -adrenergic agonist

#### \* Use of Preservative Free Formulations:

Preservative free formulations are restricted to patients with true preservative allergy and/or people with clinically significant and symptomatic ocular surface disease (evidence of epithelial toxicity and/or severe dry eyes).

Full NICE Pathway for treating and management of Glaucoma found at:

<https://pathways.nice.org.uk/pathways/glaucoma#path=view%3A/pathways/glaucoma/managing-glaucoma.xml&content=view-node%3Anodes-ocular-hypertension-treatment>

## Part 2 – Glaucoma Service Prescribing Guideline for Open Angle Glaucoma and Ocular Hypertension

Drug		With Preservative	Preservative Free
Prostaglandin analogues	1 <sup>st</sup> Line	1 <sup>st</sup> latanoprost 0.005% eye drops 2 <sup>nd</sup> bimatoprost 0.01% eye drops 3 <sup>rd</sup> travoprost 0.004% eye drops	1 <sup>st</sup> latanoprost 0.005% single use eye drops* 2 <sup>nd</sup> bimatoprost 0.03% single use eye drops*
β-blockers	2 <sup>nd</sup> Line	1 <sup>st</sup> timolol 0.25% eye drops 2 <sup>nd</sup> timolol 0.25% eye gel (long acting)	1 <sup>st</sup> timolol 0.1% eye gel*
Carbonic anhydrase inhibitors	3 <sup>rd</sup> Line	1 <sup>st</sup> brinzolamide 1% eye drops 2 <sup>nd</sup> dorzolamide 2% eye drops	1 <sup>st</sup> dorzolamide 2% single use eye drops*
α-adrenergic agonists	3 <sup>rd</sup> Line	1 <sup>st</sup> brimonidine 0.2% eye drops	

**Combination Therapies: TO BE USED WHEN COMPLIANCE/COST ISSUES ARISE**  
Choice needs to be made according to patient's concurrent and/or previous therapy

Combination Therapies	With Preservative	Preservative Free
Prostaglandin analogue + β-blocker	latanopost/timolol bimatoprost/timolol travoprost/timolol	1 <sup>st</sup> latanoprost/timolol* 2 <sup>nd</sup> bimatoprost/timolol*
Carbonic anhydrase inhibitor + β-blocker	dorzolamide/timolol brinzolamide/timolol	dorzolamide/timolol*
α-adrenergic agonist + β-blocker	brimonidine/timolol	
Carbonic anhydrase inhibitor + α-adrenergic agonist	brinzolamide/ brimonidine	

**ADD APRACLONIDINE 0.5% EYE DROP:** used short term to delay laser treatment or surgery in patients with glaucoma not adequately controlled by other drugs, however, some patients may benefit from treatment with apraclonidine 0.5% for longer periods.

**USE APRACLONIDINE PRESERVATIVE FREE 1% EYE DROP\*:** for patients who are on maximally tolerated therapy and have a preservative allergy/ocular surface disease/previous corneal surgery and are not suitable for surgery.

**ADJUNCT THERAPY:** Oral acetazolamide - for patients already on maximally tolerated topical treatment.

### OTHER GLAUCOMA DRUGS ON MEH FORMULARY (FOR RESTRICTED USE ONLY)

- Betaxolol 0.25% MR and betaxolol 0.25% MR (*preservative free*)\* – for patients who require a cardioselective β-blocker, e.g. mild asthmatics who can tolerate therapy.
- Levobunolol 0.5% (*preservative free*)\*, timolol 0.5% (long acting) and pilocarpine various strengths – secondary, atypical and refractory glaucomas.

### NON-FORMULARY

- Tafluprost 0.0015% (*preservative free*)\* – no longer initiated at Moorfields, but available for patients who have previously been initiated and are stable on this medicine.